IE
MLYS icon

Israel Englander’s Mineralys Therapeutics MLYS Stock Holding History

Israel Englander’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33M Buy
1,221,758
+696,498
+133% +$19.1M 0.01% 1209
2026
Q1 		$14.2M Buy
525,260
+446,635
+568% +$13.1M 0.01% 1836
2025
Q4 		$2.85M Sell
78,625
-325,964
-81% -$13.1M ﹤0.01% 3617
2025
Q3 		$15.3M Buy
404,589
+161,020
+66% +$3.48M 0.01% 1959
2025
Q2 		$3.3M Sell
243,569
-181,122
-43% -$2.62M ﹤0.01% 3408
2025
Q1 		$6.74M Sell
424,691
-676,983
-61% -$7.79M ﹤0.01% 2568
2024
Q4 		$13.6M Buy
1,101,674
+1,002,941
+1,016% +$13.1M 0.01% 1877
2024
Q3 		$1.2M Buy
98,733
+33,195
+51% +$402K ﹤0.01% 4125
2024
Q2 		$767K Buy
65,538
+28,198
+76% +$355K ﹤0.01% 4298
2024
Q1 		$482K Sell
37,340
-343,419
-90% -$4.24M ﹤0.01% 4853
2023
Q4 		$3.27M Buy
380,759
+16,416
+5% +$129K ﹤0.01% 3162
2023
Q3 		$3.46M Buy
+364,343
New +$4.75M ﹤0.01% 3061

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Israel Englander's MLYS Position: Q2 2026 in Review

Israel Englander increased its Mineralys Therapeutics (MLYS) stake by 133% in Q2 2026, buying an estimated $19.1M and bringing the position to 1,221,758 shares worth $33M. The position accounts for 0.01% of the portfolio, ranked #1209.

Israel Englander first reported a position in MLYS in Q3 2023 and has held it in 12 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Israel Englander held 1,221,758 shares of Mineralys Therapeutics worth $33M as of Q2 2026.
  • Israel Englander bought 696,498 Mineralys Therapeutics shares in Q2 2026, an estimated $19.1M.
  • Mineralys Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1209 holding.
  • Israel Englander first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.